Would you take Russia's Covid-19 vaccine?
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
SATURDAY, MAY 21, 2022
SATURDAY, MAY 21, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Would you take Russia's Covid-19 vaccine?

Panorama

Sam Fazeli, Bloomberg
10 January, 2021, 11:40 am
Last modified: 10 January, 2021, 12:11 pm

Related News

  • US, others walk out of APEC talks over Russia's Ukraine invasion
  • Russia stops Finland gas flow over payments dispute
  • Russia can offer 25 mln tonnes of grain for export starting on 1 Aug: UN envoy
  • Russian parliament to consider allowing over-40s to sign up for military
  • Fearing Russian cutoff, German industry braces for gas rations race

Would you take Russia's Covid-19 vaccine?

Even without seeing detailed trial data, there are reasons to be confident in the Sputnik V shot. The same can’t be said yet for China’s CoronaVac vaccine

Sam Fazeli, Bloomberg
10 January, 2021, 11:40 am
Last modified: 10 January, 2021, 12:11 pm
Russia’s shot is similar to AstraZeneca’s and appears to work just fine. Photo: Andrey Rudakov/Bloomberg
Russia’s shot is similar to AstraZeneca’s and appears to work just fine. Photo: Andrey Rudakov/Bloomberg

When it comes to Covid-19 vaccines, a lot of attention seems to have centered on the ones being made in the West. So it may come as a surprise that Russia is fifth on the list of vaccine makers with the most doses under contract through pre-purchase agreements, according to Bloomberg's Covid-19 Vaccine Tracker. The shot — whimsically named Sputnik V and developed by the Gamaleya institute — is just behind GlaxoSmithKline Plc and Sanofi's candidate in the rankings and ahead of the shots developed by Moderna Inc. and Johnson & Johnson. This is notable for a vaccine that has yet to be featured in any peer-reviewed scientific journal. How do we know we can trust it?

Russia hasn't released late-stage phase III data on its vaccine; all we have to go on are press announcements, similar to the situation with the Chinese shot made by Sinovac Biotech Ltd. The assumption is that regional health authorities have approved the Russian vaccine based on good efficacy and safety data, but there is no way of independently verifying these things without actually seeing it ourselves. That said, what we do know about Sputnik V and its design should give us some degree of confidence.

What's known: The Sputnik V has been tested in a phase III trial involving 22,714 subjects, with three interim analyses when the number of confirmed cases reached 20, 39 and 78, respectively. While the final number of cases is lower than that in the Moderna and Pfizer Inc.-BioNTech SE vaccine trials, those were larger and conducted in the U.S., where the infection rates were rising rapidly. Efficacy at each interim analysis in the Sputnik V trial was consistently at 90% or above, based on comments in press releases. There were also no cases of severe Covid-19 in vaccinated individuals, though definitions of disease severity are not clear.

As for its design, Sputnik V was developed using the kind of advanced vaccine technology employed in shots made by the AstraZeneca-Oxford University partnership and Johnson & Johnson. These two-dose vaccines use adenoviral vectors -- viruses based on the cause of the common cold that are engineered to deliver the genetic material coding for the Sars-Cov-2's key "spike" protein, which in turn prompts the immune system to mount a response to protect against further infections.

Sputnik V has one key, clever difference from the Astra and J&J vaccines: It uses the same adenovirus as J&J for the first dose (adenovirus-26) and a different adenovirus (adenovirus-5) for the second dose. In this way, it avoids the possibility of immunity to the first dose impacting the ability of the second dose to work efficiently. One issue is that a large percentage of people have pre-existing immunity to adenovirus-5, but that's not a huge drawback if the efficacy is very high. A potentially more promising alternative would be to try a combination of adenovirus-26 for the first shot and Astra's adenoviral vector – made from a chimp adenovirus – for the second, which is exactly what the two groups have agreed to do in a collaboration announced on Dec.11. 

Taken together, these details – even without the phase III results – give me reason to think the Sputnik V vaccine may well be as strong a candidate as the ones created in Western labs. The same can't be said for Sinovac's shot, CoronaVac, which is undergoing trials in Turkey, Brazil and Indonesia.

Phase III efficacy data for the CoronaVac shot has been all over the place – from 50% to more than 90% - with different numbers coming from different authorities in recent weeks. On Thursday, a Brazilian newspaper reported efficacy for the shot of 78%, adding to the confusion. This opacity does not help confidence in the vaccine. Then there is the question of the technology base. CoronaVac uses killed virus in its vaccine, mixed with a traditional adjuvant called alum. It's similar to the shot in development by French biotech firm Valneva SE, though the latter uses a potentially more powerful adjuvant from its partnership with California-based Dynavax Technologies Corp. While both may have the theoretical advantage of inducing an immune response to other parts of the virus than just the spike protein, which is the target of most other vaccines, the choice of an old adjuvant for the Sinovac shot is not great.

At some point, I hope soon, the phase III data for the Sputnik V and CoronaVac vaccines will be published in a peer-reviewed journal so that we can make up our own minds about the robustness of their efficacy and safety. As of now, though — and based on what I know so far — if I had to choose between the two, I would opt for a ride on Sputnik rather than a trip to CoronaVac's golden stars.

Author Sam Fazeli Sketch: TBS
Author Sam Fazeli Sketch: TBS

Sam Fazeli is senior pharmaceuticals analyst for Bloomberg Intelligence and director of research for EMEA


Disclaimer: This opinion first appeared on Bloomberg, and is published by special syndication arrangement

Analysis / Features / Top News

Russia / covid-19 vaccine / Sputnik V

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • A vendor wearing plastic overalls and surgical mask, waiting at his stall for buyers at Karwan Bazar. The ever-bustling marketplace has very few buyers now as many people have either left the city or are purchasing online to avoid going out. Photo: Mumit M/TBS
    Grocers’ plight as sales on credit increase
  • Photo: Collected
    Hiking gas, electricity prices now will be suicidal: FBCCI
  • Policies on cards to pave way for private heliports, helipads
    Policies on cards to pave way for private heliports, helipads

MOST VIEWED

  • The Buffalo shooter targeted Black people, linking mass migration with environmental degradation and other eco-fascist ideas. Photo: Reuters
    Eco-fascism: The greenwashing of the far right
  • Green-backed Heron on a tilting stalk. Photo: Enam Ul Haque
    Green-backed Heron: Nothing but a prayer to catch a fish  
  • Illustration: TBS
    ‘High logistics cost weakens Bangladesh’s competitiveness’
  • Mohammad (Mejbah) Mejbahuddin, Former Senior Secretary, Economic Relations Division (ERD), Ministry of Finance, Government of Bangladesh. TBS Sketch
    ‘No project is being delayed too long at the moment’
  • Dr Shamsul Hoque, Professor, Civil Engineering, BUET. TBS Sketch
    ‘Planning commission only in the name, there are no planners’ 
  • Masrur Reaz. TBS Sketch
    ‘To ensure accountability, contract financing should be based on ‘performance based payments’

Related News

  • US, others walk out of APEC talks over Russia's Ukraine invasion
  • Russia stops Finland gas flow over payments dispute
  • Russia can offer 25 mln tonnes of grain for export starting on 1 Aug: UN envoy
  • Russian parliament to consider allowing over-40s to sign up for military
  • Fearing Russian cutoff, German industry braces for gas rations race

Features

The Buffalo shooter targeted Black people, linking mass migration with environmental degradation and other eco-fascist ideas. Photo: Reuters

Eco-fascism: The greenwashing of the far right

58m | Panorama
Green-backed Heron on a tilting stalk. Photo: Enam Ul Haque

Green-backed Heron: Nothing but a prayer to catch a fish  

3h | Panorama
Illustration: TBS

‘High logistics cost weakens Bangladesh’s competitiveness’

5h | Panorama
Every morning is a new beginning for all

Seashore

5h | In Focus

More Videos from TBS

Photo: TBS

US Congress to hold first public UFO panel

1h | Videos
Pollution killing 9 million people a year

Pollution killing 9 million people a year

1h | Videos
Photo: TBS

Steps necessary to ensure economic stability

1h | Videos
Photo: TBS

The right way to apply for jobs at int'l orgs

1h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

5
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

6
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab